# About MOTS-c Direct: an independent MOTS-c peptide research digest

> MOTS-c Direct is an independent editorial project publishing cited summaries of the peer-reviewed MOTS-c peptide literature. Not a clinic, not a vendor, not medical advice.

An independent editorial digest of the published MOTS-c research — assembled tile by tile, cited to source.

## What This Site Is

MOTS-c Direct is an independent editorial project that publishes summaries of the peer-reviewed research literature on MOTS-c, the 16-amino-acid mitochondrial-derived peptide. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The model is a glazed-tile panel: a body of discrete findings — a founding metabolic paper, an exercise-mimetic physical-capacity result, a nuclear-translocation study, a 2024 direct-target paper, and a handful of human biomarker observations — set side by side and read as one composition. Each tile is cited; the gaps between them are left visible rather than filled.

## What 'Direct' Means Here

The word "direct" in the domain is editorial framing — a position this publisher takes toward the literature, reading the record straight and on the record. It is not a claim about services. MOTS-c Direct does not offer treatment, consultation, prescriptions, or supply, and it points to no vendor or pharmacy. The negative-space discipline is deliberate: this is a reading panel, not a counter.

Where the research is genuinely established, we say so plainly. Where the human evidence is thin — and for MOTS-c it is thin, with no completed interventional human efficacy trial — we mark that just as plainly. Setting marketplace enthusiasm against the actual strength of the evidence is the entire reason this digest exists.

## How We Cite

Every quantitative claim on this site maps to a numbered entry on [cited MOTS-c studies and references](/references), drawn from PubMed-indexed journals and primary FDA pages. We summarize what studies measured, in which species, at which dose, by which route. We do not provide human dosing, and we describe research findings rather than recommend any use.

We also try to be explicit about evidence class, because with MOTS-c the class is the story. A founding mechanism paper in mice, a physical-capacity result across three age groups, a single-dose acute-performance finding, a direct-binding target identified in 2024, and a set of human biomarker correlations are not interchangeable kinds of evidence — and we mark which is which rather than blending them into one confident voice. Where the regulatory record is the source, we cite the FDA page and keep to present-tense fact, never asserting a future decision.

Corrections to our reading of a paper are welcome via [MOTS-c frequently asked questions](/faq) and the contact page. If we have miscast a study's species, dose, or finding, we would rather fix the tile than defend it.

---

A cobalt-glazed azulejo panel of the MOTS-c record — the mitochondrial peptide's metabolic and exercise-mimetic findings set tile by tile and cited to source, the empty human-trial squares left openly unglazed, and the FDA 503A standing painted before anything else; no clinic behind the panel and nothing here dispensed or sold.